Repeated CBD and THC Differed in a Mouse Ischemia Model, Not a Human Stroke Trial
A mouse cerebral-ischemia experiment reported different effects of repeated CBD and THC treatment. Those findings are preclinical and should not be presented as evidence to use cannabis during a human stroke.
The model involved controlled arterial occlusion
Researchers subjected mice to middle cerebral artery occlusion and compared repeated cannabinoid regimens. They assessed reported neuroprotective outcomes, cerebral blood flow, temperature and receptor-related changes, with additional antagonist experiments.
The repeated-treatment findings diverged
The abstract reports tolerance to selected THC-related protective and temperature effects after repeated treatment, without the same tolerance pattern for CBD. Antagonist findings also supported different receptor contributions to the two compounds' effects.
The antioxidant assay was another evidence level
CBD showed antioxidant activity in a separate chemical assay. A result in that assay does not independently establish that the same mechanism caused the observed animal outcome or that an oral product would benefit a patient.
The experiment did not test emergency human treatment, long-term clinical disability or a standard-of-care comparison. Retained effects in a mouse regimen do not establish a safe clinical dose. The useful conclusion is a compound-specific research finding about repeated exposure, not a claim that CBD and THC are interchangeable or that either has proven stroke-treatment efficacy.
Related: interpreting cannabis tolerance claims.
Research cited
Hayakawa K; Mishima K; Nozako M; Ogata A; Hazekawa M; Liu AX; Fujioka M; Abe K; Hasebe N; Egashira N; Iwasaki K; Fujiwara M. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology (2007). doi:10.1016/j.neuropharm.2006.11.005. Findings discussed from the study abstract.
